LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 39.03 | EPS (ttm) | 2.71 | Insider Own | 8.23% | Shs Outstand | 22.85M | Perf Week | 3.40% |
| Market Cap | 2.42B | Forward P/E | 32.49 | EPS next Y | 3.26 | Insider Trans | -14.88% | Shs Float | 21.27M | Perf Month | 1.99% |
| Enterprise Value | 2.24B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 6.96% | Perf Quarter | -5.16% |
| Income | 63.00M | P/S | 9.44 | EPS this Y | 10.69% | Inst Trans | - | Short Ratio | 4.94 | Perf Half Y | 22.44% |
| Sales | 256.00M | P/B | 5.94 | EPS next Y | 8.53% | ROA | 9.91% | Short Interest | 1.48M | Perf YTD | 30.43% |
| Book/sh | 17.81 | P/C | 6.59 | EPS next 5Y | - | ROE | 16.19% | 52W High | 118.01 -10.36% | Perf Year | 30.53% |
| Cash/sh | 16.06 | P/FCF | 29.26 | EPS past 3/5Y | 39.41% 19.36% | ROIC | 9.43% | 52W Low | 79.40 33.22% | Perf 3Y | 67.85% |
| Dividend Est. | 1.00 (0.95%) | EV/EBITDA | 23.30 | Sales past 3/5Y | 15.56% 14.15% | Gross Margin | 72.39% | Volatility | 3.30% 3.54% | Perf 5Y | 95.35% |
| Dividend TTM | 0.90 (0.85%) | EV/Sales | 8.74 | EPS Y/Y TTM | 40.41% | Oper. Margin | 28.51% | ATR (14) | 3.79 | Perf 10Y | 648.62% |
| Dividend Ex-Date | May 21, 2026 | Quick Ratio | 12.20 | Sales Y/Y TTM | 16.36% | Profit Margin | 24.35% | RSI (14) | 61.20 | Recom | 2.30 |
| Dividend Gr. 3/5Y | 16.96% 16.05% | Current Ratio | 14.32 | EPS Q/Q | 41.67% | SMA20 | 4.66% | Beta | 0.53 | Target Price | 127.50 |
| Payout | 30.93% | Debt/Eq | 0.46 | Sales Q/Q | 11.67% | SMA50 | 8.59% | Rel Volume | 1.24 | Prev Close | 103.61 |
| Employees | 655 | LT Debt/Eq | 0.46 | Earnings | Nov 05 | SMA200 | 10.44% | Avg Volume | 324.20K | Price | 105.78 |
| IPO Date | Oct 19, 2006 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.93% -0.18% | Net Debt/EBITDA | 1.69 | Volume | 403,222 | Change | 2.09% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-06-26 | Reiterated | Lake Street | Buy | $110 → $135 |
| May-06-26 | Reiterated | Barrington Research | Outperform | $120 |
| Nov-10-25 | Reiterated | Cantor Fitzgerald | Neutral | $96 → $95 |
| Nov-05-25 | Resumed | Roth Capital | Buy | $108 |
| Aug-06-25 | Upgrade | Barrington Research | Market Perform → Outperform | |
| Feb-28-25 | Reiterated | Lake Street | Buy | $110 |
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Market Perform | |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral | $96 |
| Aug-20-24 | Reiterated | JMP Securities | Market Outperform | $100 |
| Apr-26-24 | Reiterated | Stifel Nicolaus | Hold | $75 |
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 256 | 250 | 220 | 193 | 162 | 154 | 129 | 117 | 106 | |
| Cost of Goods Sold Incl. D&A | 70 | 71 | 69 | 66 | 57 | 53 | 45 | 37 | 32 | |
| Gross Profit | 185 | 179 | 151 | 127 | 105 | 101 | 85 | 80 | 74 | |
| Selling, General and Administrative Excl. Other | 99 | 96 | 83 | 73 | 62 | 53 | 46 | 49 | 45 | |
| Research and Development | 15 | 14 | 16 | 17 | 13 | 12 | 10 | 9 | 8 | |
| Other Operating Expense | -1 | 1 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | |
| Operating Income | 73 | 68 | 52 | 37 | 27 | 36 | 29 | 21 | 28 | |
| Interest Expense | 4 | 5 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 13 | 12 | 5 | 3 | 1 | 0 | 0 | 0 | 0 | |
| Net Income Before Taxes | 81 | 75 | 57 | 39 | 27 | 34 | 27 | 22 | 28 | |
| Income Taxes | 18 | 17 | 13 | 9 | 7 | 7 | 6 | 4 | 6 | |
| Consolidated Net Income | 63 | 58 | 44 | 30 | 21 | 27 | 21 | 18 | 23 | |
| Net Income From Continuing Operations | 63 | 58 | 44 | 30 | 21 | 27 | 21 | 18 | 23 | |
| Net Income | 63 | 58 | 44 | 30 | 21 | 27 | 21 | 18 | 23 | |
| EPS (Recurring) | 2.76 | 2.55 | 1.96 | 1.36 | 0.94 | 1.27 | 1.05 | 0.91 | 1.18 | |
| EPS (Basic, Before Extraordinaries) | 2.76 | 2.55 | 1.96 | 1.36 | 0.94 | 1.27 | 1.05 | 0.91 | 1.18 | |
| EPS (Diluted) | 2.71 | 2.52 | 1.93 | 1.34 | 0.93 | 1.25 | 1.04 | 0.88 | 1.13 | |
| EBITDA | 96 | 91 | 67 | 49 | 37 | 46 | 37 | 27 | 33 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 39.03 | 32.18 | 47.74 | 42.36 | 49.48 | 40.18 | 38.94 | 40.85 | 20.92 | |
| Price To Sales Ratio | 9.50 | 7.46 | 9.21 | 6.47 | 6.25 | 6.85 | 6.28 | 6.15 | 4.24 | |
| Gross Margin | 72.27 | 71.60 | 68.64 | 65.80 | 64.81 | 65.58 | 65.89 | 68.38 | 69.81 | |
| Operating Margin | 28.52 | 27.20 | 23.64 | 19.17 | 16.67 | 23.38 | 22.48 | 17.95 | 26.42 | |
| Net Margin | 24.61 | 23.20 | 20.00 | 15.54 | 12.96 | 17.53 | 16.28 | 15.38 | 21.70 | |
| Shares Outstanding | 23 | 23 | 22 | 22 | 22 | 21 | 20 | 20 | 19 | |
| Market Capitalization | 2,433 | 1,865 | 2,027 | 1,249 | 1,012 | 1,055 | 810 | 719 | 449 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kamke Trent G | Senior V. P., Operations | May 08 '26 | Sale | 107.00 | 2,928 | 313,287 | 3,749 | May 11 |
| LeMaitre George W | Chairman and CEO | May 08 '26 | Sale | 108.69 | 27,881 | 3,030,400 | 1,430,019 | May 11 |
| Ross Bridget A | Director | May 07 '26 | Option Exercise | 48.15 | 5,044 | 242,882 | 8,986 | May 11 |
| Ross Bridget A | Director | May 07 '26 | Sale | 111.10 | 5,044 | 560,366 | 3,942 | May 11 |
| Jasinski Lawrence J | Director | May 07 '26 | Option Exercise | 65.92 | 2,858 | 188,412 | 8,657 | May 11 |
| Jasinski Lawrence J | Director | May 07 '26 | Sale | 110.00 | 3,943 | 433,730 | 4,714 | May 11 |
| LeMaitre George W | Chairman and CEO | May 07 '26 | Sale | 107.64 | 18,600 | 2,002,013 | 1,457,900 | May 11 |
| Pellegrino Joseph P JR | Director | Apr 22 '26 | Option Exercise | 35.48 | 2,941 | 104,347 | 15,021 | Apr 23 |
| Kamke Trent G | Senior V. P., Operations | Mar 11 '26 | Sale | 108.50 | 2,625 | 284,813 | 6,677 | Mar 13 |
| Roberts David B | President and Director | Mar 11 '26 | Sale | 107.68 | 3,312 | 356,586 | 14,667 | Mar 13 |
| Kamke Trent G | Senior V. P., Operations | Mar 11 '26 | Option Exercise | 35.48 | 2,625 | 93,135 | 9,302 | Mar 13 |
| LeBlanc Dorian Paul | Chief Financial Officer | Mar 10 '26 | Option Exercise | 0.00 | 2 | 0 | 2,400 | Mar 12 |
| LeMaitre George W | Chairman and CEO | Mar 02 '26 | Sale | 107.81 | 55,930 | 6,030,020 | 1,476,500 | Mar 02 |
| Kamke Trent G | Senior V. P., Operations | Feb 27 '26 | Sale | 110.29 | 1,044 | 115,143 | 6,677 | Mar 02 |
| Roberts David B | President and Director | Feb 27 '26 | Sale | 106.80 | 8,464 | 903,958 | 17,979 | Mar 02 |